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PREFACE 
Objective of the Research Project 
The objectives of this project are to propagate the pCI 7 .1-CTCF recombinant 
constructs in bacteria, followed by miniplasmid preparation of the plasmids using alkaline 
method, characterization of the construct and to use it in the Conventional Calcium 
Phosphate transfection experiments. 
Background of the Research Project 
CTCF is a protein that binds to the boundary elements in a methylation-dependent 
manner. CTCF is already exist and being expressed in HeLa cell line and will produce 
protein bands following Western blotting with appropriate primary and secondary 
antibodies. The use for transforming and transfecting CTCF into the HeLa cells is that so 
that it can be over expressed during protein assay, after treating with respective antibodies. 
The method used in transfecting the gene is by manual method, and not using a kit, 
that is calcium-phosphate method. Using transfection kits are easier since nowadays there 
are lots of transfection kits available for expression research, but all the kits are expensive 
require a big amount of money to purchase it, so the transfection using calcium phosphate 









pCI-CTCF is transformed into Escherichia coli (E.coli) bacteria, and then 
transfected into human cervical cancer (HeLa) cell line for overexpression. The 
overexpression can be detected by protein assay such as Western Blot and the positive 
results for this overexpression may indicate that the research study is a success and 
transfection using calcium phosphate method can always be practiced in the research field 
for its low cost instead of the expensive transfection kits. 
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Transformation of pCI-CTCF plasmid was done after receiving this recombinant 
construct from Dr. Elena M. Klenova, Gene Regulation Laboratory, University of Essex, 
UK. The plasmid was propagated in E.coli DHS-a competence cell. Following 
transformation, a transformant containing the recombinant plasmid was selected and 
cultured overnight in LB Broth. The plasmid was then extracted using a plasmid extraction 
kit QIAprep Spin Miniprep Kit (QIAGEN, Germany). Purified plasmid was further 
analysed and characterized. The plasmid was then transfected into HeLa cells using 
Calcium Phosphate method. Following transfection, the HeLa cells were lysed and the 
supernatant of the lysed cells was analysed using Sodium Dodecyl Sulfate Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) followed by Western Blotting using anti CTCF 
monoclonal antibody. There is a positive expression of exogenous CTCF detected in the 
lysate compare to the normal HeLa cell lines control. However due to short period of time 
for this project, transfection-efficiency was not properly estimated. This work established 
conventional, cheap and reasonable transfection method for future functional assay works 
in the lab. 
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ABSTRAK 
Transfonnasi plasmid pCI-CTCF dijalankan setelah menerima binaan rekombinan 
ini daripada Dr. Elena M. Klenov~ Gene Regulation Laboratory, University of Essex, UK. 
Plasmid ini dipropagasikan di dalam kompeten sel E.co/i DH5-a. Diikuti dengan 
transfonnasi, transforman yang mengandungi plasmid rekombinan telah dipilih dan 
dikulturkan semalaman di dalam LB Broth. Plasmid ini kemudiannya diekstrak dengan 
menggunakan kit pengekstrakan plasmid QIAprep Spin Miniprep Kit (QIAGEN, 
Germany). Plasmid yang telah dipurifikasikan dianalisis dengan lanjut dan digambarkan 
sifatnya. Kemudian plasmid ini ditransfek ke dalam sel HeLa dengan menggunakan 
kaedah Kalsium Fosfat. Selepas transfeksi, sel He La dilisiskan dan supernatant dari sel 
yang dilisiskan itu dianalisa dengan menggunakan Sodium Dodecyl Sulfate Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) diikuti Western Blotting menggunakan anti CTCF 
monoklonal antibodi. Terdapat ekspresi positif pada eksogenus CTCF yang dikesan di 
dalam lisat berbanding dengan normal sel HeLa kontrol. Bagaimanapun, disebabkan 
kesuntukan masa untuk projek ini, kecekapan transfeksi tidak dapat diestimasikan . dengan 
sempurna. Penyelidikan ini berjaya membangunkan kaedah yang murah dan sesuai untuk 
proses transfeksi bagi kegunaan asai berfungsi di dalam makmal pada masa hadapan. 
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1.0 INTRODUCTION AND LITERATURE REVIEW 
1.1 Human Cervical Cancer and BeLa Cell Line 
Cervical carcinoma is caused mostly by infection with a high-risk group of human 
papillomaviruses (HPV) (Lorincz et a/., 1987, zur Hausen, 1989, Cullen et a/., 1991). 
After high-risk HPV infection, two viral oncogenic proteins, E6 and E7, play a critical role 
in inducing cervical cancers by interacting with p53 and pRB, respectively and in 
inactivating these cellular regulatory proteins (Scheffner eta/., 1990, Werness eta/., 1990, 
Scheffner et a/., 1991 ). The two viral oncogenic proteins, E6 and E7 are commonly 
• 
expressed in these carcinoma cells and are required for maintaining cancer malignancy 
(Santin et a/., 1998). 
It has been reported that, except for cervical cancers, most cancer development 
results from p53 gene mutation (Levine, 1997). p53 mutation is detected in more than 50% 
of cancer cells, but rarely in cervical cancer cell types (Greenblatt eta/., 1994). In most 
cervical cancers, however, the function of p53 is down-regulated by the E6 protein of HPV 
16, whereby E6 binds to p53, resulting in degradation of E6-p53 complexes through the 
ubiquitin pathway (Hamada eta/., 1996, Pim and Banks, 1999, Kessis eta/., 1993). 
For instance, human cervical cancer cell lines, such as CaSki (HPV 16), SiHa (HPV 
16), HeLa (HPV 18) and HeLaS3 (HPV 18) express intact p53 protein (Woong eta/., 
2002). HeLa cell line that was used in this research project was HeLa cell line. Generally 











commercially available. The cell line was derived from cervical cancer cells taken from 
Henrietta Lacks, who died from her cancer disease on October 4, 1951. HeLa cell lines are 
treated as cancer cells, as they are descended from a biopsy taken from a visible lesion on 
the cervix as part of the diagnosis of Ms. Lacks' cancer. 
HeLa cells are termed immortal because they can divide an unlimited number of 
times in the laboratory cell culture plate as long as fundamental cell survival conditions are 
met, that is the cells are being maintained and sustained in a suitable environment. There 
are many strains of HeLa cells as they continue to evolve by being grown in cell cultures, 
but all HeLa cells are descended from the same tumor cells removed from Ms. Lacks. It 
has been estimated that the total number of HeLa cells that have been propagated in cell 
culture far exceeds the number of cells in Henrietta Lacks' body. 
1.2 CTCF as a multivalent multifunctional protein 
CCCTC-binding factor (CTCF) is a versatile zinc finger protein (11-zinc-finger 
transcriptional factor) with unusual multiple DNA sequence binding specificity (Klenova et 
a/., 1998) and with diverse regulatory functions and ubiquitously expressed gene 
upregulated during the S-G2 stage of the cell cycle. It is an exceptionally highly conserved 
protein displaying 93% overall identity and 100% identity in the 11-zinc-finger DNA-
binding domain between avian and mammalian amino acid sequences (Filippova et a/., 
1996). 
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CTCF encodes a nuclear factor containing three major, functionally distinct regions 
with amino acid sequences that were maintained practically identical throughout vertebrate 
evolution: a DNA-binding domain (composed of 11 ZFs), and two flanking trans-acting 
transcriptional repressor/activator regions that account for approximately two-thirds of the 
entire protein. 
CTCF is a protein that binds to the boundary elements in a methylation-dependent 
manner. One of the well characterized examples of such element is the ICR (imprinting 
control region). It is situated in the 5'-flank of the HJ9 gene and 90 kb downstream of Ig/2 
gene (Thorvaldsen et al., 1998, Kanduri et al., 2000). This domain, which is maternally 
unmethylated and paternally methylated, regulate the expression of the maternal allele of 
the lgf2 gene (Bartolomei and Tilghman, 1997). The differentially methylated imprinting 
control region (ICR) upstream of the H19 gene regulates allelic lg/2 expression by means of 
a methylation-sensitive chromatin insulator function (Pant et al., 2004 ). 
Moreover, CTCF was recently found to be a parent of an origin-specific and 
methylation-sensitive structural and functional component of the chromatin insulator 
upstream of the H19 gene (Bell and Felsenfeld, 2000, Hark et al., 2000, Kanduri et al., 
2000), thus suggesting a new important role for a CpG-containing subset of CTSs (CTCF-
target Sequences) in control of genomic imprinting (Kanduri et al., 2000). 
Recent studies on transcriptional control of gene expression have pinpointed the 
importance of long-range interactions and three-dimensional organization of chromatins 
within the nucleus. Distal regulatory elements such as enhancers may activate transcription 
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over long distances; hence, their action must be restricted within appropriate boundaries to 
prevent illegitimate activation of non-target genes. Insulators are DNA elements with 
enhancer-blocking and/or chromatin-bordering functions. In vertebrates, the versatile 
transcription regulator CCCTC-binding factor (CTCF) is the only identified trans-acting 
factor that confers enhancer-blocking insulator activity. CTCF-binding sites were found to 
be commonly distributed along the vertebrate genomes (Bao et al., 2008). 
A study of cohesion mediates transcriptional insulation by CCCTC-binding factors 
that was done by Wendt et al., 2008 indicate functions of cohesion that act at CTCF-
binding sites, which may function as transcriptional insulators or boundary elements in 
vertebrate genomes and the cohesion itself is just like CTCF, that is widely expressed in 
mammalian tissues, most of which are predominantly composed of postmitotic cells. 
CTCF has been described in vertebrates and Drosophila and it is conceivable that the main 
function of CTCF in mammalian genomes is to define binding sites for cohesion, and that 
cohesion is the molecule that structures DNA in a way that cause insulator and boundary 
effect (Wendt et al., 2008). 
CTCF is a truly multifunctional factor, because depending on the context, distinct 
50- to 60-bp-long CTSs bound through combinatorial contributions of ZFs, mediate a 
variety of distinct functions. In this study, the c-myc promoter was employed as a model of 
the CTCF -binding regulatory target to demonstrate that the presence of posttranslational 
modifications at the strictly conserved C-terminal serines, which we mapped for the frrst 
time, can affect transcriptional activity of the protein. Attempts to investigate possible 
effects of phosphorylation on CTCF-driven regulation of diverse chromatin insulators 
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(Allshire and Bickmore, 2000) and of negative nuclear receptor-binding hormone-
responsive elements (A wad et al., 1999, Burcin et a/., 1997) are currently underway. 
It is clear, however, that for better understanding of why under-phosphorylated 
CTCF partially loses its ability to inhibit cell growth, direct comparison of the whole 
expression spectrum of target genes, for example by a microarray technology, will be 
required. Recent review of Ohlsson et al., 2001, established CTCF as a true 'multivalent 
multifunctional' protein that utilizes different sets of ZFs to form distinct complexes with 
varying -50 bp CTCF-target sequences (CTSs) that mediate distinct functions in regulation 
of gene expression. Binding of targeting sequence elements by CTCF can block the 
interaction between enhancers and promoters, therefore limiting the activity of enhancers to 
certain functional domains. Besides acting as enhancer blocking, CTCF can also act as a 
chromatin barrier by preventing the spread of heterochromatin structures. 
The family of nucleic acid-binding C2H2 type zinc finger transcription factors is 
divided into two classes. One class consists of small proteins (Gli1, Krox-20, WT1, Egr-1, 
and Sp 1) with conserved zinc finger clusters of 3 to 5 units, while the other class (ZNF91, 
ZNF74, ZFP37, CTCF) can contain more than 10 zinc finger clusters. CTCF is a 
ubiquitously expressed, highly conserved transcription factor that contains 10 C2H2- and 1 
C2H-type zinc-finger motifs. 
CTCF was first described as a factor that binds to the chicken c-myc promoter 
(Lobanenkov et al., 1990) and to the silencer element of the chicken lysozyme gene 
(Baniahmad et al., 1990, Burcin et al., 1997). CTCF binds to diverse sequences by 
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utilizing different combinations of essential zinc finger (Filippova et al., 1996, Burcin et 
a/., 1997). Consequently, a defined DNA recognition sequence cannot readily be 
recognized. The function of CTCF in gene regulation is also diverse. For example, CTCF 
binds to the chicken lysozyme silencer 2.4 kilobase pairs upstream from the transcriptional 
start site (V ostrov et a/., 2002). 
CTCF -mediated repression may include binding to insulator regions between 
enhancers and promoters resulting in enhancer blocking. CTCF has been found to 
directionally block enhancer activation by binding to the insulator element at the 5' end of 
the chicken P-globin gene locus and similar CTCF-binding sequences were identified in a 
variety of insulators from diverse vertebrate species, suggesting a widespread role for 
CTCF in the regulation of enhancer-activated genes (Bell et a/., 1999). CTCF binds to the 
promoter-proximal regions of the chicken c-myc gene where it acts either as a 
transcriptional repressor or activator (Lobanenkov et a/., 1990, Klenova et al., 1993, 
Klenova et a/., 1997) as the nuclear factor CTCF was first identified as one of the factors 
binding to the regulatory regions of the c-myc gene (Dunn and Davie, 2003). 
In the human and mouse c-myc, genes CTCF binds to divergent sequences that 
coincide with RNA polymerase pausing sites within the transcribed region of the genes 
(Filippova et al., 1996). CTCF gene may be a candidate tumor suppressor gene, since it 
localizes to a narrow cancer-specific rearrangements such as in breast cancer patients. It 
shows that CTCF transcriptional regulation may be important for cell cycle progression, 
differentiation, apoptosis, and tumorigenesis. Functions of varying CTCF /DNA complexes 
may be regulated by posttranslational protein modifications (Klenova et al., 2001 ); by 
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physical interactions with other multifunctional nuclear proteins, which include, among 
others, RNA/DNA binding factor YB-1 (Chemukhin et al., 2000); and the repression-
associated mSin3AIHDACs (Lutz et al., 2000); and by attenuation of the interactions with 
DNA via specific methylation of CpG pairs involved in recognition of specific CTSs by the 
protein (Kanduri et al., 2000). 
However, despite the fact that CTCF emerged as an important player in networks 
linking expression domains with epigenetics and cell-growth regulatory processes, there 
was no investigation of the possible effects, if any, of CTCF on cell growth. Based on 
Rasko et a/., 2001, in different experimental systems, ectopic expression of CTCF does not 
lead to an acute cell death but results in a severe cell-growth inhibition involving a nearly-
complete blockade of DNA replication and cell division. Together, these events lead to a 
dramatic inhibition of cell clonogenic capacity. 
1.3 pCI Mammalian Expression Vector 
The mammalian expression vector used in this research project was pCI mammalian 
expression vector. This vector can be obtained from Promega Corporation, Madison, WI, 
USA. The pCI mammalian expression vector is designed to promote constitutive 
expression of cloned DNA inserts in mammalian cells. The major difference between the 
pCI and pSI mammalian expression vectors is the enhancer/promoter region controlling the 
expression of the inserted gene. The pCI expression vector contains the human 
cytomegalovirus (CMV) major immediate-early gene enhancer/promoter region (Table 
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1.3.1 and Figure 1.3.1). This vector can be used for both transient and stable expression of 
genes. 
For stable expression, the pCI vector must be co-transfected with an expression 
vector containing a selectable gene for mammalian cells. The pCI vector's CMV 
enhancer/promoter region enables strong, constitutive expression in many cell types. A P-
globinllgG chimeric intron located downstream of the enhancer/promoter region can further 
increase expression. The late SV 40 polyadenylation signal increases the steady-state level 
of RNA approximately fivefold more than the early SV 40 polyadenylation signal. Also, 
multiple cloning sites exist for easy insertion of eDNA and it is versatile, where synthesize 
transcripts in vitro using the T7 RNA polymerase promoter or generate single-stranded 
DNA in E. coli using the fl origin of replication. 
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pCI Mammalian Expression vector sequence reference points (Whole size 4006 bp) 
Description of Gene (s)/Marker Position 
Cytomegalovirus immediate-early enhancer/promoter region 1-742 
Chimeric intron 857-989 
T7 -EEV sequencing primer binding site 1020-1041 
T7 RNA Polymerase Promoter ( -17 to + 2) 1034-1052 
T7 promoter transcription start site 1051 
Multiple cloning region 1052-1104 
SV40 late polyadenylation signal 1111-1332 
Phage fl region 1422-1877 
Beta-lactamase (AmpR) coding region 2314-3174 
Table 1.3 .1 : pCI mammalian expression vector sequence reference points, based on 
the pCi vector from Promega Corporation, Madison, WI, USA. 
T7 Transcription Start 
I • 
51 ••. CTIAATACGACTCACTATAGGCTAGCCTCGAGAATTCACGCGT 
I 1 II II II I 
T7 Promoter Nhe I Xho I EcoR I M!u I 
Smal 
I I 
GGTACCTCTAGAGTCGACCCGGGCGGCCGC ... 3' 
I !I I! I I' I I 
Kpn I Xba I Ace I SstZ I 
Sail Noll 
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Figure 1.3.2: Schematic presentation ofpCI 7.1-CTCF (Shaharum, 2002) 
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1.4 Calcium Phosphate Transfection 
An important technique in biological research is that of expressing exogenous DNA 
in a variety of mammalian cell backgrounds. Introduction of the plasmid DNA into the 
cell, however, has been problematic. A variety of techniques for DNA introduction have 
been employed, including DNA complex formation with calcium phosphate, 
diethylaminoethyl dextran, or cationic lipids, direct introduction via direct injection, 
electroporation, microprojectiles, or fusion with liposomes, and use of recombinant viruses. 
Of these methods, DNA complex formation techniques are the simplest and least 
expensive, requiring neither the specialized equipment of direct introduction methods nor 
the generation of a new recombinant virus for each DNA. 
In fact, novel transcriptional regulatory elements, as well as various RNA 
processing and translational signals, have been discovered by using DNA transfection of 
tissue culture cell. Based on Chen and Okayama, 1987, nearly a dozen transfection 
techniques have been devised, all of which involve the use of either calcium phosphate to 
deliver DNA into cells, osmotic shock or treatment with lysosomal inhibitors to enhance 
the transfection efficiencies and recently, a method involving the use of high-voltage 
electric pulses to create pores in membranes has been devised for delivering DNA into 
cells. These transfection methods are quite useful for examining the transient expression of 
DNA, but they are inefficient for stable transformation. 
While the calcium phosphate transfection method is a very efficient means of 
introducing DNA into cells in many cell systems, it is very inefficient in many others. This 
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